|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Pharmacyclics Inc.
PCYC
|
|
|
+10.56%
in
499 days
Pharmacyclics, Inc., a pharmaceutical company, is developing drugs to treat cancer and other diseases. Its pharmaceutical agents are synthetic small molecules designed to target key biochemical pathways in diseased cells. The company’s product candidate, Xcytrin (motexafin gadolinium) Injection, an anti-cancer agent with a novel mechanism of action, has completed Phase III trials in oncology and is in Phase II trials for patients with non-small cell lung cancer. Its products also include PCI-24781, a histone deacetylase inhibitor in Phase I trial in patients with advanced relapsed < /><><><><><><>< /><><><><><><><><>...
|
PCYC CEO confident of approval
PCYC
|
|
|
-35.18%
in
892 days
The stage is now set for Pharmacyclics to finally be heard by the FDA. With Dendreon breaking the mold at the FDA the stage is now set for approval of Xcytrin. The CEO is urging the FDA to assemble a panel and review the drug for approval in June.
|
FDA files NDA for Pharmacyclics drug Xcytrin
PCYC
|
|
|
+1.52%
in
3 days
(closed on 04/26/07)
Today, the FDA filed the NDA for Xcytrin. In most cases this would be great news. However, they chose to review the drug over the next 8 months and have until Dec 31st t to make their final decision to approve or not. Given that Xcytrin was designated a fast track and Orphan drug it was surprising they chose the longer time frame for review.
Long term the news is still good for Pharmacyclics but this extended delay will likely cause the stock price to drop back into the high $2 to low $3 range.
|
Pharmacyclics Challenges FDA
PCYC
|
|
|
+19.27%
in
19 days
(closed on 04/23/07)
Pharmacyclics is a small start-up pharmaceutical company that has developed a novel cancer treatment for small-cell lung cancer. Their drug Xcytrin received Orphan drug status and was placed on the fast track due to the promising results of initial trials and the uniqueness of the drug. They recently completed phase III trials with an international study. The study results initially did not show significant results. When exploring further it was determined that the non-US portion of the population received initial treatment significantly later in the process following diagnosis than the< />< /><>...
|
Pharmacyclics Challenges FDA
PCYC
|
|
|
+19.27%
in
19 days
(closed on 04/23/07)
Pharmacyclics is a small start-up pharmaceutical company that has developed a novel cancer treatment for small-cell lung cancer. Their drug Xcytrin received Orphan drug status and was placed on the fast track due to the promising results of initial trials and the uniqueness of the drug. They recently completed phase III trials with an international study. The study results initially did not show significant results. When exploring further it was determined that the non-US portion of the population received initial treatment significantly later in the process following diagnosis than the< />< /><>...
|
From the Blogosphere
The Week's Top Insider Buys
The week's top insider transaction by dollar amounts.
Community Bankers Acquisition Corp (BTC)- $4,675,000
Information Services Group Inc (III)- $3,075,000
eLoyalty Corp (ELOY)- $2,297,000
Pharmacyclics Inc (PCYC)- $2,082,000
TCF Financial Corp (TCB)- $2,009,000
Perini Corp (PCR)- $1,887,000
Marchex Inc (MCHX)- $1,815,000
Powerwave Technologies Inc (PWAV)- $1,604,000
Enterprise Products Partners L P (EPD)- $1,557,000
Align Technology Inc (ALGN)- $1,467,000
Huntsman Corp New (HUN)-...
Continued at Todd Sullivan's ValuePlays
|
The Week's Top Insider Buys
|
|
|
The week's top insider transaction by dollar amounts.<>
Community Bankers Acquisition Corp (BTC)- $4,675,000
Information Services Group Inc (III)- $3,075,000
eLoyalty Corp (ELOY)- $2,297,000
Pharmacyclics Inc (PCYC)- $2,082,000
TCF Financial Corp (TCB)- $2,009,000
Perini Corp (PCR)- $1,887,000
Marchex Inc (MCHX)- $1,815,000
Powerwave Technologies Inc (PWAV)- $1,604,000
Enterprise Products Partners L P (EPD)- $1,557,000
Align Technology Inc (ALGN)- $1,467,000
Huntsman Corp New (HUN)- $1,270,000
Dick's Sporting Goods Inc (DKS)- $1,254,000
ev3 Inc (EVVV)- $1,066,000
Insight Enterprises Inc (NSI...
|
The Week's Top Insider Buys
|
The week's top insider transaction by dollar amounts.<>
Community Bankers Acquisition Corp (BTC)- $4,675,000
Information Services Group Inc (III)- $3,075,000
eLoyalty Corp (ELOY)- $2,297,000
Pharmacyclics Inc (PCYC)- $2,082,000
TCF Financial Corp (TCB)- $2,009,000
Perini Corp (PCR)- $1,887,000
Marchex Inc (MCHX)- $1,815,000
Powerwave Technologies Inc (PWAV)- $1,604,000
Enterprise Products Partners L P (EPD)- $1,557,000
Align Technology Inc (ALGN)- $1,467,000
Huntsman Corp New (HUN)- $1,270,000
Dick's Sporting Goods Inc (DKS)- $1,254,000
ev3 Inc (EVVV)- $1,066,000
Insight Enterprises Inc (NSI...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on PCYC |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Pharmacyclics Inc.
- Answers.com
